CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application August 7, 2020
Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets June 15, 2020
Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases May 29, 2020
Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call April 6, 2020
Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies April 2, 2020
Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com March 10, 2020
